130676-65-2 Usage
Uses
Used in Pharmaceutical Industry:
N-Formyl-L-leucine (3S,4S,6S)-3-Hexyltetrahydro-2-oxo-6-undecyl-2H-pyran-4-yl Ester is used as an impurity in the synthesis of Orlistat (O686500) for its role in the development and production of weight loss medications. Its presence as an impurity is significant for quality control and ensuring the safety and efficacy of the final pharmaceutical product.
Used in Chemical Research:
As a by-product during the synthesis of N-Formyl-L-leucine (3S,4R,6S)-3-Hexyltetrahydro-2-oxo-6-undecyl-2H-pyran-4-yl Ester (F700570), N-Formyl-L-leucine (3S,4S,6S)-3-Hexyltetrahydro-2-oxo-6-undecyl-2H-pyran-4-yl Ester may be utilized in chemical research to study its properties, potential applications, and to optimize the synthesis process for the desired compound.
Used in Deuterated Analogs:
As a deuterated analog of an impurity in the synthesis of Orlistat, N-Formyl-L-leucine (3S,4S,6S)-3-Hexyltetrahydro-2-oxo-6-undecyl-2H-pyran-4-yl Ester may be employed in research involving isotope labeling techniques. These techniques are valuable for understanding the behavior of molecules in various chemical and biological processes, as well as for developing new drugs and materials with improved properties.
Check Digit Verification of cas no
The CAS Registry Mumber 130676-65-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,0,6,7 and 6 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 130676-65:
(8*1)+(7*3)+(6*0)+(5*6)+(4*7)+(3*6)+(2*6)+(1*5)=122
122 % 10 = 2
So 130676-65-2 is a valid CAS Registry Number.
InChI:InChI=1/C29H53NO5/c1-5-7-9-11-12-13-14-15-16-18-24-21-27(25(28(32)34-24)19-17-10-8-6-2)35-29(33)26(30-22-31)20-23(3)4/h22-27H,5-21H2,1-4H3,(H,30,31)/i3D3
130676-65-2Relevant academic research and scientific papers
Tetrahydrolipstatin: Thermal and hydrolytic degradation
Stalder,Schneider,Oesterhelt
, p. 1022 - 1036 (2007/10/02)
The thermal and hydrolytic degradation of tetrahydrolipstatin (THL, 1) was investigated. All main degradation products were isolated, characterized, and synthesized. Labile intermediates unavailable to isolation were detected and identified by GC/MS analysis of their silylated derivatives, and whenever possible, compared with independently prepared reference compounds. The identified degradation products represent at least 97% of the total degradation mixture. Two main reaction pathways are proposed. Pharmacological data are reported for the degradation mixture and the main degradation products.
